ReachMD
Be part of the knowledge.™Episodes 1-15 of 18
NSCLC Therapy Management and Biomarker Testing
CME/CE Broadcast ReplayNSCLC Therapy Management and Biomarker Testing
Preventing Disease Recurrence with Adjuvant Therapy in Stage IIB/IIC Melanoma
CME/CEPreventing Disease Recurrence with Adjuvant Therapy in Stage IIB/IIC Melanoma
Getting on Board with Real-World Evidence About CDK 4/6 Inhibitors for HR+/HER2- mBC: Stay on Track with Shared Decision-Making
CME/CEGetting on Board with Real-World Evidence About CDK 4/6 Inhibitors for HR+/HER2- mBC: Stay on Track with Shared Decision-Making
Closing the Gap to Care: Assessing CAD and Improving Patient Outcomes with Revascularization
CME/CEClosing the Gap to Care: Assessing CAD and Improving Patient Outcomes with Revascularization
Talking Rare: Epidemiology and Pathogenesis of APOL1-Mediated Kidney Disease
CME/CETalking Rare: Epidemiology and Pathogenesis of APOL1-Mediated Kidney Disease
Optimizing Bone Health in Postmenopausal Post-Fracture Patients
CME/CEOptimizing Bone Health in Postmenopausal Post-Fracture Patients
What Are the Data Supporting Neoadjuvant Therapy in Melanoma?
MinuteCE®What Are the Data Supporting Neoadjuvant Therapy in Melanoma?
Panel: Preserving Operability: How To Manage irAEs in the Perioperative Setting During Neoadjuvant Treatment of Melanoma?
MinuteCE®Panel: Preserving Operability: How To Manage irAEs in the Perioperative Setting During Neoadjuvant Treatment of Melanoma?
Panel: Discussing Neoadjuvant/Adjuvant ICI-Based Therapy With Patients and Caregivers
MinuteCE®Panel: Discussing Neoadjuvant/Adjuvant ICI-Based Therapy With Patients and Caregivers
Panel: Critical Considerations in the Use of ICIs in High-Risk Resectable Melanomas
MinuteCE®Panel: Critical Considerations in the Use of ICIs in High-Risk Resectable Melanomas
Should a Patient With a BRAF-Mutated Tumor Receive Targeted vs ICI Neoadjuvant Therapy?
MinuteCE®Should a Patient With a BRAF-Mutated Tumor Receive Targeted vs ICI Neoadjuvant Therapy?
Panel: How and When Should I Assess Response to Neoadjuvant and Adjuvant ICI Therapy?
MinuteCE®Panel: How and When Should I Assess Response to Neoadjuvant and Adjuvant ICI Therapy?
What Are the Data Supporting Adjuvant Therapy in Melanoma?
MinuteCE®What Are the Data Supporting Adjuvant Therapy in Melanoma?
What Is the Rationale for Neoadjuvant and Adjuvant Therapy in Melanoma?
MinuteCE®What Is the Rationale for Neoadjuvant and Adjuvant Therapy in Melanoma?
